PDCD1 and cancer: Interestingly, the combination of LAG-3 blockade with PD-1 blockade exhibited a stronger antitumor efficacy than either treatment alone, suggesting that LAG-3 could be a potential therapeutic target for combination therapies with PD-1 blockade in MHC-II expressing cancers [168].